A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer - Wikidata - wikimedia - TriplyDB

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

http://www.wikidata.org/entity/Q34051972

about

HER2 testing in gastric cancer: An update Advanced gastric cancer: Current treatment landscape and future perspectives Changing strategies for target therapy in gastric cancer Personalized medicine in gastric cancer: Where are we and where are we going?Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Companion diagnostics for the targeted therapy of gastric cancer Gastric Cancer: New Drugs - New Strategies Biologic therapy in esophageal and gastric malignancies: current therapies and future directions Clinical impact of tumour biology in the management of gastroesophageal cancer Recent advances in the HER2 targeted therapy of gastric cancer Da0324, an inhibitor of nuclear factor-κB activation, demonstrates selective antitumor activity on human gastric cancer cells Targeted therapy in gastroesophageal cancers: past, present and future.Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.Targeted therapy in gastric cancer.Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.Emerging mAbs for the treatment of esophagogastric cancer.Novel biomarkers for the identification and targeted therapy of gastric cancer.Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Targeting HER 2 and angiogenesis in gastric cancer.Pertuzumab in gastrointestinal cancer.Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Gastric cancer management: Kinases as a target therapy.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.Structural basis of a novel heterodimeric Fc for bispecific antibody production.Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines.Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.New therapeutic options opened by the molecular classification of gastric cancer.Biomarkers of gastric cancer: Current topics and future perspective

P2860

Q26746253-FC2DB752-7A2A-4268-BFAF-97387CB98F9C Q26764934-A6409B60-7C69-4FC8-9796-A10DB62AEA5D Q26774513-AE3473FC-676D-4DDE-B09F-F271A7FEA896 Q26774521-2C6E81DC-A742-4F4A-96F9-B735C6597051 Q26776198-DD55F5EE-0338-4553-84CB-146145808B80 Q26780298-C7812B91-D17C-4EB9-AFDA-D17B185F1374 Q27028079-C0908EF9-AFEB-418C-BBFE-FCBD7F5FCB72 Q33895597-ECF5A909-1736-4A7E-877C-4A16900BFFFD Q33922534-C3D7FDBF-06A0-4B31-ADF5-6C8CA6171E06 Q34967104-52701D6A-C2AC-43B1-B3D8-D34240002F65 Q35978864-79E185C2-F7B2-491C-992C-ACA0A5413C85 Q36294579-813173BA-260D-4997-A984-77669B5E76A4 Q37001973-7193E788-C234-427C-91F3-307E3027E0B2 Q37341824-CE868125-8086-4E74-8AE9-5C7F084B789E Q37703226-C6C045EE-3D1F-4F38-918F-6103A8F1220E Q38253835-0F26311B-E817-4AA0-9A29-CB94CCD85F10 Q38284597-B2520CCF-D2C9-41D7-AC04-789A2A4455A8 Q38556435-940EF7DF-DCEC-42CE-9219-F563B0376927 Q38632917-4D82FBF4-2A46-415C-A4A1-5C39A69AE1F4 Q38633308-665D3E83-0B6C-4F27-8E5C-C300C4D2A01F Q38653309-0DD0F3AC-CE82-46DA-8FE1-94C977F76858 Q38653626-53DD16E0-906B-479E-8165-6BF6D3FE2114 Q38720829-4EEC3367-A0C2-4F86-B432-FF09B5D8FA9F Q38749038-EF597D06-0550-4308-A8A1-4DD2DB99648A Q38823374-3B7663C3-2AEE-4034-8C35-A74C03AA2DE9 Q39630965-8B3C4021-F3ED-4874-AF50-5ABEE9FABE33 Q41612592-E515B49F-5B22-46AC-92BC-2C2757859800 Q47564950-86675FE2-767E-4502-93CB-A83FEB911C59 Q47636102-8A380DB1-7EA4-447C-9A04-8B1099817C6A Q54109361-8A040193-2407-4C29-ABD7-F94F0E9EEF59 Q55527185-731B9EA8-05E4-42D3-AF42-C006B7187C1F Q57176090-13608925-3CF1-4BC3-900F-0AE556B8E949

P2860

A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer

http://www.wikidata.org/entity/Q34051972

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@ast

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@en

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@nl

type

label

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@ast

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@en

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@nl

prefLabel

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@ast

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@en

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@nl

P1433

Q34051972-C8C5F794-98E5-4EE2-9AA8-BE3AC5D942BE

P1476

Q34051972-FC0E84DE-560D-4E01-AC8E-2988A92F0768

P2093

Q34051972-0EB7A297-BA6D-445C-BADF-66F4720CA5A7

Q34051972-16F672EA-E534-46AE-A1D8-5BC67CDDBAF9

Q34051972-226CCB81-EFC3-4A4A-8D58-23BFDB619E81

Q34051972-49E271C6-7248-4646-AC10-E21EE130414F

Q34051972-5A7B7A6D-0913-4200-AA9D-EDAB151D3E34

Q34051972-A976DE65-264A-4488-90FC-AE99DAFD24F2

P2860

Q34051972-0D8EEB7A-2826-4740-A1C8-FBD450BDE51E

Q34051972-14552D96-9B60-4C8B-8975-A228FA28FACD

Q34051972-151FB288-45CC-4F72-94A7-81F3F5D75C21

Q34051972-161FA696-3C76-47C9-A912-4ACEA22B7787

Q34051972-16F4DB71-30A4-41ED-A8B7-32FCE098B13C

Q34051972-1A34E911-9AF1-4A97-AAA2-4B077B0D5F80

Q34051972-21FA4322-8861-4C83-BA54-671BC7E2C1D2

Q34051972-2A458ADB-F666-408F-8A68-7414F58B0003

Q34051972-2C2AC3D3-46A9-472B-A06D-882BA30AE66A

Q34051972-34E8F47A-06B3-4FE5-A2B2-B5D5FC24CC7D

P2888

Q34051972-8DF05122-720A-4D04-BC61-658896A2E995

P304

Q34051972-C538D975-4BD1-4BDD-8D04-81D918315D18

P31

Q34051972-FD3B2F4B-7A69-4683-947F-0665CD09599A

P356

Q34051972-DF73DB14-CB82-4FFB-BD46-E60984026805

P407

Q34051972-7A63D7EE-B441-4C07-B7C9-A3D1302B5354

P433

Q34051972-F04C0B6B-28CD-4401-B057-E1DE134B77C8

P478

Q34051972-3A7AE9E6-222D-477B-9A6D-801F8826EC8C

P50

Q34051972-7FCF3ED7-CA97-42CD-A5BD-E95D23681B1F

Q34051972-ABC9B9AD-AC9E-4D97-BF59-0EC979FC4FD8

P577

Q34051972-250C651A-F490-4298-9E68-74FC3F90A8EB

P6179

Q34051972-5D48B4EB-DE6F-4696-9DEA-2CF18032884F

P698

Q34051972-02C85908-402A-4844-A6DE-8ABF0E34D4B2

P921

Q34051972-0887B1CC-8EC1-4380-97F7-99B769C7A208

P932

Q34051972-8874543F-D761-4025-BF3D-864667FE99CB

P356

P1433

British Journal of Cancer

P1476

A phase IIa dose-finding and s ...... sitive advanced gastric cancer

@en

P2093

A Garg

http://www.w3.org/2001/XMLSchema#string

P Tassone

http://www.w3.org/2001/XMLSchema#string

R Yu

http://www.w3.org/2001/XMLSchema#string

T Szado

http://www.w3.org/2001/XMLSchema#string

Y-J Bang

http://www.w3.org/2001/XMLSchema#string

Y-K Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

P2888

P304

660-666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.356

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043539745

http://www.w3.org/2001/XMLSchema#string

P698

24960402

http://www.w3.org/2001/XMLSchema#string

P921

P932

4134501

http://www.w3.org/2001/XMLSchema#string